WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innova
Jul 10, 2008
July 10, 2008 - Shanghai, China - WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it was awarded one of the top 20 "China Most Innovative Enterprises" and its CEO Dr. Ge Li was named one of the top 10 "Most Innovative Leaders of Chinese Enterprises" at the 8th China Enterprise Innovation Forum held in Beijing last month.
Having successfully run for seven years, China Enterprise Innovation Forum aims to stimulate innovation by Chinese companies and help construct China into an innovative country. Commemorating the 30th anniversary of China's reform and opening up, this year's annual forum was attended by a number of high-ranking government officials. The nomination committee consisting of various leading experts and scholars from the National Development and Reform Commission, State-owned Assets Supervision and Administration Commission of the State Council, Research Office of the State Council, Chinese Academy of Social Sciences and Peking University, took six months to select the winning companies and individuals. The selection was based on four criteria: innovation, public trust, impact and enabling force.
WuXi PharmaTech won the award because it is the pioneer and leader in China's rapidly growing pharmaceutical R&D outsourcing service industry; a research driven and customer-focused company that has shown the world that high-quality drug R&D and strict IP protection in China are attainable; a responsible corporate citizen committed to environmental and social welfare; and it is an undeniable force that is replacing the "Made in China" model with "Innovated in China".
"It is a great honor that WuXi is named one of the top-20 most innovative companies in China. I am very glad that our integrated service business model is recognized once again by the Chinese government as an innovation. China is becoming an increasingly important part of the global drug and medical device value chain. I hope with more government support the modern service industry in China will become more sophisticated and mature," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.